Previous 10 | Next 10 |
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
Image source: The Motley Fool. Reata Pharmaceuticals, inc (NASDAQ: RETA) Q2 2021 Earnings Call Aug 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Reata Pharmaceuticals, inc (RETA) Q2 2021 Earnings Call Transcrip...
Reata Pharmaceuticals, Inc. (RETA) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Warren Huff – Chief Executive Officer Colin Meyer – Chief Research and Development Officer Manmeet Soni – Chief Operating and Chief Financial Officer Confere...
PRE-NDA MEETING WITH FDA SCHEDULED FOR Q3 2021 ON OMAVELOXOLONE FOR PATIENTS WITH FA AND REATA ANNOUNCES PLAN TO FILE OMAVELOXOLONE NDA DURING Q1 2022 PROVIDES UPDATE FROM MID-CYCLE COMMUNICATION MEETING ON BARDOXOLONE FOR PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME ...
ACM, AMC, APPS, ATCO, CABO, CBT, CCXI, CF, CHGG, CMBM, CMP, COMP, CXW, DDD, DHT, DOOR, ELY, ESE, ETH, EVBG, FGEN, FLGT, HALO, HBM, HLIO, INO ,IPAR, MESA, MODN, NCMI, NHI, NTR, OSH, PEN, PLNT, PRPL, QLYS, RCKT, REAL, RETA, RGNX, RPAY, SAIL, SDC, STE, TPTX, VUZI, WES, ZIOP For Seeking Alpha's f...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs after the market ...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Stanley Druckenmiller’s 13F portfolio value increased from $3.71B to $3.89B this quarter. Duquesne added Citigroup and Palantir Technologies while dropping Walt Disney. The top three positions are at 25% of the portfolio. For further details see: Tracking Stanley ...
Reata Pharmaceuticals has enjoyed robust appreciation over the years, as the company advances two lead medicines (bardoxolone and omaveloxolone). Bardoxolone has an upcoming approval for chronic kidney disease related to Alport's syndrome. There are also other data catalysts for b...
PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in a virtual Fireside chat and...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...